Quantum Biopharma Files 6-K Report
Ticker: QNTM · Form: 6-K · Filed: Mar 30, 2026 · CIK: 0001771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-issuer, regulatory-filing
TL;DR
Quantum Biopharma filed a 6-K on 3/30/26, check the press release for updates.
AI Summary
Quantum Biopharma Ltd. filed a Form 6-K on March 30, 2026, reporting its status as a foreign issuer. The filing includes a press release as Exhibit 99.1. The company's mailing and business address is 55 University Avenue, Suite 1003, Toronto, Ontario, Canada.
Why It Matters
This filing indicates ongoing reporting activity for Quantum Biopharma Ltd., a foreign issuer, which is important for investors tracking the company's regulatory compliance and disclosures.
Risk Assessment
Risk Level: low — A 6-K filing is a routine report for foreign issuers and does not inherently signal significant risk.
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Filer
- 0001771885 (company) — CIK Number
- 2026-03-30 (date) — Filing Date
- 55 UNIVERSITY AVENUE, SUITE 1003 TORONTO Ontario, Canada M5J 2H7 (address) — Mailing and Business Address
FAQ
What type of filing is this?
This is a Form 6-K, a Report of foreign issuer.
When was this filing accepted by the SEC?
The filing was accepted on March 30, 2026.
What is the CIK number for Quantum Biopharma Ltd.?
The CIK number for Quantum Biopharma Ltd. is 0001771885.
Where is Quantum Biopharma Ltd. located?
Quantum Biopharma Ltd.'s mailing and business address is 55 University Avenue, Suite 1003, Toronto, Ontario, Canada.
What is included as an exhibit in this filing?
Exhibit 99.1, a press release, is included in this filing.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2026-03-30 07:50:09
Filing Documents
- f6k_033026.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 16KB
- 0001171843-26-002008.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: March 30, 2026 /s/ Donal Carroll Donal Carroll Chief Financial Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated March 30, 2026